- Home
- CIF vs BOLD Comparison
CIF vs BOLD Comparison
Compare CIF & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CIF | BOLD |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 28.0M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | CIF | BOLD |
|---|---|---|
| Price | $1.71 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 43.9K | ★ 123.4K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.47 | $1.00 |
| 52 Week High | $1.77 | $2.67 |
Technical Indicators
Market Signals| Indicator | CIF | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 52.31 |
| Support Level | $1.70 | $1.21 |
| Resistance Level | $1.73 | $1.34 |
| Average True Range (ATR) | 0.01 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 33.33 | 47.62 |
Price Performance
Historical ComparisonAbout CIF MFS Intermediate High Income Fund
Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.